Combination of Stomach-Specific Indicators with Cancer-Associated Biomarkers in Serum Can Improve the Accuracy to Predict Gastric Cancer
Liping Sun,Hua-kang Tu,Tie-jun Chen,Jing-wei Liu,Quan Yuan,Nan-nan Dong,Yuan
DOI: https://doi.org/10.1016/j.cgh.2016.09.094
IF: 13.576
2016-01-01
Clinical Gastroenterology and Hepatology
Abstract:The first two authors contributed equally to this work Currently, there are two major classes of serological biomarkers for early detection of gastric cancer (GC): stomach-specific biomarkers and cancer-associated biomarkers. The combination of both may increase accuracy. Here, we investigated whether the combination of serum pepsinogens (PGs), anti-Helicobacter pylori IgG (HpAb, both stomach-specific biomarkers), and osteopontin (OPN, classified as a cancer-specific biomarker) can be used to screen GC. Serum samples were collected from 365 GC patients and 729 healthy individuals; 332 cases and 332 age- and sex-matched controls were selected for the matched analysis. Serum biomarker levels were measured by ELISA. Logistic regression and receiver operator characteristic curve were used to assess the association of biomarkers with GC and the discriminative performance of biomarkers for GC. Among the matched samples, serum PGI/II ratio (PGR), HpAb, and OPN were significantly associated with GC. For discriminating GC, the area under the receiver operator characteristic curve for triple combination PGR-HpAb-OPN (0.826) was significantly higher than for dual combinations PGR-HpAb (0.786, P<0.001), PGR-OPN (0.787, P<0.001), and OPN-HpAb (0.801, P=0.006), as well as PGR (0.735, P<0.001), HpAb (0.737, P<0.001), and OPN (0.713, P<0.001) alone. With a diagnostic cut-off point of 0.607, the predictive power of the triple combination had 62.4% sensitivity, 89.2% specificity, and 75.8% accuracy in matched samples and 62.2% sensitivity, 90.5% specificity, and 81.1% accuracy in all samples. The combination of serum PG, HpAb and OPN could improve predictive accuracy for GC. This novel panel has the potential to efficiently screen the patients at high risk of GC.